Jennifer Arnold, MD

Jennifer Arnold, MD

Assistant Professor, Neurology
Neurology

    About me

    Gender

    Female

    Education & training

    Positions
    Neurologist
    Medical School
    MD, University of Illinois
    Doctorate Degree
    Ph.D. Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign
    Undergraduate Degree
    BS Biology, Southeast Missouri State University
    Residency
    Neurology, University of Michigan
    Fellowship
    Neurodegenerative Diseases, University of Michigan

    Clinical trials

    Trial
    Neurology

    A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients with Early Alzheimer’s Disease (BenfoTeam)

    Active recruiting

    The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine, to determine whether it delays or slows the progression of the symptoms of early Alzheimer’s disease.  

    Contact: Stephanie Kohlrus 217-545-3013
    Trial
    Neurology

    Annovis - A Randomized, Double-Blind, Placebo-Controlled, Dose-ranging, Multicenter Study of Buntanetap in Participants with Mild to Moderate Alzheimer's Disease

    Active recruiting

    The purpose of this study is to assess the efficacy and safety of Buntanetap in participants with mild to moderate Alzheimer's Disease participants.

    Contact: Sara Boarman 217-545-6829
    Trial
    Neurology

    Annovis - A Randomized, Double-Blind, Placebo-Controlled, Dose-ranging, Multicenter Study of Buntanetap in Participants with Mild to Moderate Alzheimer's Disease

    Active recruiting

    The purpose of this study is to assess the efficacy and safety of Buntanetap in participants with mild to moderate Alzheimer's Disease participants.

    Contact: Sara Boarman 217-545-6829
    Trial
    Neurology

    Open-Label Extension of Studies ATH-1017-AD-0201 and ATH-1017-AD-0202 in Subjects with Mild to Moderate Alzheimer's Disease

    Active not recruiting

    ATH-1017-AD-203: The purpose of this study is to determine the safety and tolerability of ATH-1017 in patients with mild to moderate Alzheimer's disease.

    Contact: Sara Boarman 217-545-6829
    Trial
    Neurology

    Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

    Active not recruiting

    I5T-MC-AACI:  The purpose of this study is to assess the effect of donanemab versus placebo on clinical regression in participants with early symptomatic Alzheimer's disease with presence of low-medium tau pathology.

    Contact: Sara Boarman 217-545-6829
    Trial
    Neurology

    Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

    Active not recruiting

    I5T-MC-AACI:  The purpose of this study is to assess the effect of donanemab versus placebo on clinical regression in participants with early symptomatic Alzheimer's disease with presence of low-medium tau pathology.

    Contact: Sara Boarman 217-545-6829